Real-World watch: tracking a rare neurological disease over five years
NCT ID NCT05966467
Summary
This study aims to collect long-term, real-world data on how well specific C5 inhibitor medications control relapses and affect quality of life for adults with AQP4+ NMOSD, a rare autoimmune disorder that attacks the nerves in the eyes and spinal cord. It will follow 122 participants who are already taking these medications as part of their standard care for approximately five years. The goal is to understand the real-world effectiveness and safety of these treatments outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
-
Clinical Trial Site
RECRUITINGColumbus, Ohio, 43215, United States
Contact
-
Clinical Trial Site
RECRUITINGPlano, Texas, 75024, United States
Contact
-
Clinical Trial Site
RECRUITINGMilwaukee, Wisconsin, 53215, United States
Contact
-
Clinical Trial Site
RECRUITINGBuenos Aires, Argentina
-
Clinical Trial Site
NOT_YET_RECRUITINGBuenos Aires, Argentina
-
Clinical Trial Site
RECRUITINGBuenos Aires, Argentina
-
Clinical Trial Site
RECRUITINGBuenos Aires, Argentina
Contact
Contact
Contact
Contact
-
Clinical Trial Site
RECRUITINGBurnaby, British Columbia, Canada
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGBeijing, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGGuangzhou, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGHenan, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGShanghai, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGSichuan, China
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGWuhan, China
Contact
-
Clinical Trial Site
RECRUITINGDresden, Germany
Contact
-
Clinical Trial Site
RECRUITINGEssen, Germany
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGMünchen, Germany
Contact
-
Clinical Trial Site
RECRUITINGNaples, Italy
Contact
-
Clinical Trial Site
RECRUITINGFukuoka, Japan
Contact
-
Clinical Trial Site
RECRUITINGKawasaki, Japan
Contact
-
Clinical Trial Site
RECRUITINGMiyagi, Japan
Contact
-
Clinical Trial Site
NOT_YET_RECRUITINGTokyo, Japan
Contact
-
Clinical Trial Site
RECRUITINGDaejeon, South Korea
Contact
-
Clinical Trial Site
RECRUITINGGyeonggi-do, South Korea
Contact
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, South Korea
Contact
Contact
Contact
Contact
Contact
Contact
-
Research Site
RECRUITINGBoston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.